This study tested whether low-amplitude shocks delivered via 2 field electrodes were capable of terminating atrial fibrillation in isolated perfused canine atria. Our expectation was that the fields induced by the 2 physical electrodes would create many "virtual" electrodes that could then be used to overdrive-pace the fibrillating tissue and thereby terminate fibrillation. The observation that this method, which we call far-field antifibrillation pacing, converted atrial fibrillation reliably (93% success rate) with the use of field strengths that were only 13% of the energy required to cardiovert with a single shock suggests that this method may have clinical utility. Cardioversion of atrial fibrillation with the use of lower energies could reduce the pain and tissue damage associated with a large single shock and prolong the battery life of implantable devices. Further experimental studies are needed, however, to optimize the shock protocol and to determine whether far-field antifibrillation pacing is effective and safe in vivo. See p 467.
Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia
Diagnosis of arrhythmogenic right ventricular dysplasia (ARVD) relies on results of diagnostic tests that screen for structural abnormalities of the right ventricle, ventricular arrhythmias, a family history of sudden death or ARVD, and ECG abnormalities that have been linked to ARVD. Among the many diagnostic tests that are used to screen patients for ARVD, the ECG is of particular importance because of its widespread availability and low cost. In this study, we performed a systematic analysis of the 12-lead ECG in ARVD patients compared with controls. To our knowledge, this is the first study to evaluate the ECG features of ARVD patients on the basis of the presence or absence of a complete or incomplete right bundle-branch block (RBBB). This is of particular importance because incomplete RBBB or complete RBBB patterns are commonly observed in patients with ARVD. The results of this study reveal that in the absence of a complete RBBB or incomplete RBBB, T-wave inversion through V 3 is the single ECG parameter that demonstrates optimal sensitivity and specificity. Second, for patients with an incomplete RBBB pattern, T-wave inversion through V 3 is also the single ECG parameter that demonstrates optimal sensitivity and specificity. Third, for patients with a complete RBBB pattern, an rЈ/s ratio of Ͻ1 in V 1 was the single ECG parameter that demonstrates optimal sensitivity and specificity. It is our hope that the findings of our study will be confirmed in other populations of ARVD patients and that, in future, the ECG can be relied on with greater confidence as a screening tool for ARVD. See p 477.
Shortage of Cardiothoracic Surgeons Is Likely by 2020
Even as the burden of cardiovascular disease in the United States is increasing as the population grows and ages, the number of active cardiothoracic surgeons has fallen for the first time in 20 years. This study evaluates current and future requirements for cardiothoracic surgeons in light of decreasing rates of coronary artery bypass grafting procedures. By 2025, the demand for cardiothoracic surgeons could increase by 46% on the basis of population growth and aging if current healthcare use and service delivery patterns continue. Even with complete elimination of coronary artery bypass grafting, there is a projected shortfall of cardiothoracic surgeons because the active supply is projected to decrease 21% over the same time period as a result of retirement and declining entrants. This shortage of cardiothoracic surgeons within the next 10 years could diminish quality of care if non-board-certified physicians expand their role in cardiothoracic surgery or if patients must delay appropriate care because of a shortage of well-trained surgeons. See p 488.
Lower Mortality From Coronary Heart Disease and Stroke at Higher Altitudes in Switzerland
Previous studies have suggested that living at higher altitude provides an advantage with respect to cardiovascular disease. However, these studies had serious limitations and yielded conflicting results. We assessed on an individual level the association between altitude and mortality from stroke and coronary heart disease in the general population of German-speaking Switzerland living between 259 and 1960 m above sea level. We found that mortality decreased with increasing altitude and that the effect was stronger for coronary heart disease and in men. In addition, being born at higher altitude provided an independent and sustained beneficial effect on coronary heart disease mortality. Lower mortality at higher altitude did not appear to depend on variations in classic cardiovascular disease risk factors or in sociodemographic characteristics but rather could result from physiological adaptations to altitude or differences in climate (eg, ultraviolet exposure). Our findings not only substantiate the concept of a protective effect of altitude on cardiovascular disease mortality but also suggest a dose-dependent and sustained effect. See p 495.
Predictive Value of Brachial Flow-Mediated Dilation for Incident Cardiovascular Events in a Population-Based Study: The Multi-Ethnic Study of Atherosclerosis
Since Celermajer et al introduced brachial flow-mediated dilation (FMD) testing as a measure of endothelial function, numerous studies have associated FMD with cardiovascular risk factors. Some authors have even hypothesized that FMD is a "barometer" of cumulative cardiovascular insult to the vascular endothelium, implying that accurate measurement of FMD will in fact be an important way of assessing global cardiovascular risk. Current methods of FMD measurement coupled with unknown biological factors that influence the acquisition have contributed to the variability of FMD. Despite this variability, FMD has been shown to be predictive of cardiovascular events in elderly and high-risk cohorts. Data on the predictive value of FMD in subjects free of cardiovascular events and cohorts with low cardiovascular risk are limited. The present study uses the largest cohort thus far studied and showed that FMD predicts incident cardiovascular events in population-based adults free of clinical cardiovascular disease. Like other new biomarkers, the addition of FMD to the Framingham Risk Score (FRS) did not improve the discriminative ability of the FRS for cardiovascular events in this population in receiver operating characteristic analysis. However, reclassification analysis showed that the addition of FMD to FRS net reclassified 29% of subjects in this cohort correctly as low, intermediate, and high risk compared with FRS alone. The addition of FMD to FRS mainly improved the net reclassification of the intermediate-risk group (28%), a group that the FRS has been less accurate in classifying. Standardization and studies addressing the variability of FMD are needed. See p 502.
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Location of Cardiac Arrest in a City Center: Strategic Placement of Automated External Defibrillators in Public Locations
The optimal treatment of out-of-hospital cardiac arrests caused by ventricular fibrillation is defibrillation, and the chance of survival is strongly dependent on early defibrillation. This finding has inspired the placement of automated external defibrillators (AEDs) in public locations for use by lay responders, the principle behind publicaccess defibrillation. To save lives, AEDs should be placed where the risk of cardiac arrest is high. The Copenhagen experience indicates that AED deployment according to the European Resuscitation Council guidelines (1 cardiac arrest every 2 years) requires AED coverage of 1% of a the city area and coverage of 20% of all the cardiac arrests in public areas. A much greater impact can be achieved with the American Heart Association guidelines (1 cardiac arrest every 5 years), in which AED coverage of Ϸ10% of the city covers nearly 70% of the cardiac arrests. If there is no local knowledge of the high-incidence cardiac arrest areas in a particular city, then placement should be focused on major transportation sites and public areas where the population density is very high. AED placement based on local or political initiatives cannot be discouraged; however, if used alone, this study revealed a risk of inconsistent AED placement in the community, with placement being primarily in low-incidence areas of cardiac arrest. To avoid this situation, strategic initiatives focusing on high-incidence areas of cardiac arrest should be a necessary part of any public-access defibrillation program. See p 510.
Effectiveness of Emergency Response Planning for Sudden Cardiac Arrest in United States High Schools With Automated External Defibrillators
Sudden cardiac arrest is the leading cause of death in exercising young athletes. Several US guidelines provide recommendations for emergency planning for sudden cardiac arrest and advocate for the placement of automated external defibrillators in the school and athletic setting. Many schools have not implemented automated external defibrillator programs because of financial limitations, liability concerns, or both. Of the 11% of high schools responding to this survey, 82% had an automated external defibrillator on school grounds. Of those with automated external defibrillators, 82% had an emergency action plan in place, and 2.1% had had a sudden cardiac arrest event within the preceding 6 months. Victims were older nonstudents, including teachers, staff, and spectators, or student athletes. No arrests were reported in student nonathletes. The majority of victims survived to hospital discharge. This study provides further support for the implementation of automated external defibrillators programs in US high schools. See p 518.
Circulating Transforming Growth Factor-␤ in Marfan Syndrome
Recent evidence suggests that transforming growth factor-␤ (TGF-␤) antagonism through losartan may be an effective treatment for Marfan syndrome (MFS). In the absence of empirical data, the dose of losartan or other medications currently used in people with MFS is based largely on dosing regimens for hypertension. Consideration of dosing may be particularly important because natural genetic variation in MFS can influence effective levels of and intrinsic response to drug therapy. This highlights the need for an informative biomarker-prognostic, therapeutic, or both-in MFS. We report that a genetically defined mouse model of MFS, which recapitulates many manifestations of the disease including progressive aortic root dilatation, shows elevated circulating TGF-␤ concentrations. Furthermore, circulating TGF-␤ levels show close correlation with aortic root dimension in mice, diminish on treatment with losartan in a dose-dependent manner, and are fully normalized in mice that show a robust therapeutic response. As in the mouse model, we observed elevated circulating TGF-␤ concentrations in people diagnosed with MFS, and those levels decreased after treatment with losartan or ␤-blocker. However, we did not observe a close correlation between circulating TGF-␤ levels and the aortic root size or Z scores in humans. The use of circulating TGF-␤ to individualize patient counseling and management is appealing because the assay is monitoring a central and direct effector of disease progression. Even if there is little intrinsic prognostic value to a snapshot measurement of circulating TGF-␤, observing TGF-␤ over time in the individual patient might yield important information on progression of the disease, response to therapy, or both. See p 526.
